CIM
ANIK icon

Calvert Investment Management’s Anika Therapeutics ANIK Stock Holding History

Calvert Investment Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-61,974
Closed -$3.03M – 46
2016
Q4 		$3.03M Buy
61,974
+315
+0.5% +$14.6K 0.11% 242
2016
Q3 		$2.95M Buy
61,659
+23,864
+63% +$1.18M 0.11% 246
2016
Q2 		$2.03M Hold
37,795
– – 0.08% 254
2016
Q1 		$1.69M Sell
37,795
-33,675
-47% -$1.37M 0.07% 245
2015
Q4 		$2.73M Buy
+71,470
New +$2.73M 0.12% 168

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Calvert Investment Management's ANIK Position: Q1 2017 in Review

Calvert Investment Management sold out of Anika Therapeutics (ANIK) in Q1 2017, closing a stake of 61,974 shares — an estimated $3.03M sold.

Calvert Investment Management first reported a position in ANIK in Q4 2015 and held it in 5 quarters. The position peaked at $3.03M in Q4 2016. 156 funds tracked by Wall St. Rank hold ANIK as of Q1 2017.

  • Calvert Investment Management reported no remaining Anika Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Calvert Investment Management sold 61,974 Anika Therapeutics shares in Q1 2017, an estimated $3.03M.
  • Calvert Investment Management first reported a position in Anika Therapeutics in Q4 2015 and held it in 5 quarters.
  • Calvert Investment Management's Anika Therapeutics position peaked at $3.03M in Q4 2016.
  • 156 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2017.

Based on Calvert Investment Management's 13F filing for Q1 2017.